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Summary
Atomic-resolution structures of the transmembrane 7-α-helical domains of 26 G-protein-coupled receptors
(GPCRs) (including opsins, cationic amine, melatonin, purine, chemokine, opioid, and glycoprotein hormone
receptors and two related proteins, retinochrome and Duffy erythrocyte antigen) were calculated by distance
geometry using interhelical hydrogen bonds formed by various proteins from the family and collectively applied as
distance constraints, as described previously [Pogozheva et al., Biophys. J., 70 (1997) 1963]. The main structural
features of the calculated GPCR models are described and illustrated by examples. Some of the features reflect
physical interactions that are responsible for the structural stability of the transmembraneα-bu dle: the formation
of extensive networks of interhelical H-bonds and sulfur–aromatic clusters that are spatially organized as ‘polarity
gradients’; the close packing of side-chains throughout the transmembrane domain; and the formation of inter-
helical disulfide bonds in some receptors and a plausible Zn2+ binding center in retinochrome. Other features of
the models are related to biological function and evolution of GPCRs: the formation of a common ‘minicore’
of 43 evolutionarily conserved residues; a multitude of correlated replacements throughout the transmembrane
domain; an Na+-binding site in some receptors, and excellent complementarity of receptor binding pockets to
many structurally dissimilar, conformationally constrained ligands, such as retinal, cyclic opioid peptides, and
cationic amine ligands. The calculated models are in good agreement with numerous experimental data.
Introduction
The rhodopsin-like G-protein-coupled receptors
(GPCRs) form a unique family of hundreds of proteins
which transduce chemical and optical signals through
the cytoplasmic membrane by activating intracellular
G-proteins [1]. Electron microscopy studies of sev-
eral rhodopsins [2–4] have clearly shown that these
receptors consist of seven transmembraneα-helices.
Furthermore, the presence, in each transmembrane
helix, of several characteristic residues conserved
throughout the rhodopsin-like GPCRs indicates that
all proteins in the family share a common 3D structure
[5]. The existence of a minimum sequence homol-
ogy of∼20% between remotely related GPCRs leads
to an estimated 1.6–2.3 Å root mean square devia-
tion (rmsd) of main-chain atoms within theα-helical
∗To whom correspondence should be addressed.
core, using a calibration curve relating the coordinate
rmsd and sequence identity for proteins with known
3D structures [6].
GPCRs, especially rhodopsin itself, have been
extensively studied by site-directed mutagenesis and
by a variety of physicochemical methods. These ex-
perimental data and the analysis of variability and
hydrophobicity patterns in amino acid sequences of
GPCRs have made possible the identification of the
transmembrane helices of GPCRs and their unequivo-
cal assignment to the peaks in EM maps [5] and the
construction of various approximate GPCR models.
Modeling of the transmembrane domain is simplified
by the identification of residues that are evolution-
arily conserved or hydrophilic, or which are impor-
tant for folding or ligand binding of GPCRs. These
residues form the protein interior, thus defining a lipid-
inaccessible surface of each transmembrane helix and
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Table 1. GPCR transmembraneα-bundle models calculated by distance geometry with H-bonding constraints; the listed agonists and
antagonists were docked with the receptor models
Identifier Accession number Receptor name Agonists Antagonists
1 OPRD_BOVIN P02699 Bovine rhodopsin All-trans retinal 11-cis retinal
2 OPSR_HUMAN P04000 Red cone opsin All-trans retinal 11-cis retinal
3 OPSB_HUMAN P03999 Blue cone opsin All-trans retinal 11-cis retinal
4 OPSD_XENLA P29403 Frog rhodopsin All-trans retinal 11-cis retinal
5 OPSD_PROCL P35356 Crayfish All-trans retinal 11-cis retinal
Rhodopsin
6 REIS_TODPA P23820 Squid 11-cis retinal All-trans retinal
Retinochrome
7 A2AA_HUMAN P08913 α2A-adrenergic Clonidine
8 B2AR_HUMAN P07550 β2-adrenergic Epinephrine Carazolol, iodoazidobenzylpindolol
Isopreterenol
9 D2DR_HUMAN P14416 Dopamine D2A Dopamine Spiperone
10 5H1A_HUMAN P08908 Serotonin 5HT1A Serotonin Spiperone
11 HH2R_HUMAN P25021 Histamine H2 Histamine
12 ACM1_HUMAN P11229 Muscarinic m1 Acetylcholine Atropine, pirenzepine
13 ACM3_HUMAN P20309 Muscarinic m3 Acetylcholine
14 ML1A_HUMAN P48039 Melatonin Melatonin
15 OPRD_HUMAN P41143 δ-opioid JOM-13 Naltrindole
16 OPRM-MOUSE P42866 µ-opioid Morphine Naloxone
17 OPRK_HUMAN P41145 κ-opioid U69,593 Norbinaltorphimine
18 OPRX_HUMAN P41146 Orphanin
19 IL8A_HUMAN P25024 CXC chemokine
20 IL8B_HUMAN P25025 CXC chemokine
21 LCR1_HUMAN P30991 CXC fusin
22 CKR5_HUMAN P51681 CC chemokine
23 US28_HCMVA P09704 CC chemokine
24 G74_HSUSA Q01035 Herpesvirus saimiri
25 HSDARC X85785 Duffy antigen
26 AA2A_HUMAN P29274 Adenosine A2A Adenosine
27 P2UR_HUMAN P41231 ATP ATP
28 LSHR_HUMAN P22888 Lutropin/choriogonadotropin
Coordinates for all receptor models listed are available from our Web site at http://www.umich.edu/∼him. The structures of bovine
rhodopsin complexed with 11-cis retinal and all-transretinal have been deposited in the Protein Data Bank (PDB files: 1bok and 1boj,
respectively).
placing a restriction on rotational orientation of the
helix and the depth of its immersion into theα-bundle
[5,7,8]. GPCR models typically have been built from
seven ‘ideal’ helices with arbitrarily chosen side-chain
conformers (or without side chains at all) to satisfy the
published two-dimensional EM maps, restrictions on
rotational orientations of the helices, and some con-
straints derived from mutagenesis and cross-linking
data [9–14]. Perhaps the best model of this type has
recently been developed by fitting two kinked and five
straightα-helices to electron cryomicroscopy three-
dimensional (3D) maps of frog rhodopsin [15]. Never-
theless, the resolution currently achieved by electron
microscopy of rhodopsins (∼7.5 Å in the membrane
plane and 16.5 Å in the perpendicular direction, Refer-
ence 3) is insufficient to obtain atomic-level structure,
since individual residues are not visible in the maps.
Therefore, we have developed, specifically for the
modeling of GPCRs, a purely geometrical approach
that relies on distance constraints, as in calculations
of protein structures from NMR spectroscopy data
[16]. The approach consists of an iterative distance
geometry refinement of an approximate initial model
using an evolving system of hydrogen bonds, formed
by intramembrane polar side-chains in various pro-
teins in the family and collectively applied as distance
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constraints [16,17]. The models of 26 rhodopsin-like
GPCRs and two related proteins have been calculated
using this method (Table 1).
Three features make GPCRs especially attrac-
tive for structural analysis: (i) Similar to bacteri-
orhodopsin, apoferritin, and glucoamylase, GPCRs
formα-bundles containing many polar residues within
a generally hydrophobic protein ‘core’. This accen-
tuates the clustering of residues with similar polar-
ities, which is less apparent in structures of typical
water-soluble proteins with more uniformly nonpolar
interiors. (ii) The sequence identity between remotely
related members of the family is only∼20% within
the common transmembrane core. This provides an
opportunity to compare many different variations of
side-chain packing, all of which must be compatible
within essentially the same 3D structure. (iii) Al-
though GPCRs are structurally similar, their native
ligands are of vastly different structure and size, from
small cationic amines to medium-sized proteins. In
this review, we discuss key features of our GPCR
models and show that they are consistent with gen-
eral principles of protein structure. In addition, we
compare the models with the most recently published
electron microscopy data for rhodopsin [3,15] and
with mutagenesis studies of cationic amine receptors.
Atomic-resolution models of GPCRs calculated by
distance geometry with hydrogen bonding
constraints
The approach developed to construct the models de-
scribed here is based upon the presence of numer-
ous polar residues in the transmembrane segments
of GPCRs. It is known that water-inaccessible polar
groups of proteins have a strong tendency to form
H-bonds [18]. In transmembraneα-helices, backbone
peptide groups are already paired, while the polar side-
chains must interact with each other to form intra- or
interhelical H-bonds. The candidate H-bonding pairs
can be identified from the analysis of sequence align-
ments as polar residues that appear and disappear si-
multaneously in various GPCRs and by using approx-
imate receptor models to exclude all spatially distant
residues from the list of possible correlations. H-bonds
thus identified can be applied as distance constraints
for the packing of the transmembraneα-helices, using
the distance geometry algorithm. Since the rhodopsin-
like GPCRs share a common 3D structure of the
transmembrane domain, the side-chain H-bonds from
many different GPCRs can be combined in order to
increase the number of simultaneously applied con-
straints and to calculate an ‘average’ 7-α-bundle struc-
ture. This average structure is subsequently used to
restrain the positions of the transmembrane helices in
the calculation of the 7-α-bundle for ‘specific’ GPCRs.
The computational procedure, described elsewhere
[16], was organized as an iterative refinement with
evolving constraints that begins with an initial, ap-
proximate model of theα-bundle and continues until
each buried polar side-chain of each of the 410 GPCRs
considered participates in at least one hydrogen bond
in the final structure. Each iteration of the refinement
included (i) examination of the structures calculated
in the previous iteration for additional or alterna-
tive H-bonds, for correlations in sequence alignments,
and for structural flaws, such as buried polar groups
lacking any H-bonds, violations of constraints,α-
helices multiply curved by contradictory constraints
or loosely packed because of insufficient constraints,
or hindrances or holes produced by incorrectly packed
side-chains; (ii) modification of distance and angle
constraints (H-bonds and conformers of side-chains)
to correct detected flaws and to increase the number
of simultaneously formed H-bonds; and (iii) distance
geometry calculations with the modified constraints
using the program DIANA [19]. The analysis of cal-
culated structures (step (i)) was performed using the
programs ADJUST [16] and QUANTA (Molecular
Simulations Inc.). The constraints and the correspond-
ing α-bundle structure simultaneously evolved during
the refinement. The search for the proper side-chain
conformers and H-bonds was guided primarily by cor-
relations in multiple sequence alignments of GPCRs.
The final ‘average’ 7-α-bundle structure, obtained
after>500 iterations of the refinement procedure, dif-
fers significantly from the initial structure: the rmsd
of Cα atoms of the initial and final structures was
∼4 Å. In the final model, each water-inaccessible
polar side-chain of all 410 sequences considered (col-
lectively,>20000 side-chains) participates in at least
1 H-bond. This ‘saturation of H-bonding potential’
criterion was very sensitive to errors during the re-
finement. The transmembrane segments of individual
GPCRs are hydrophobicand contain less than 30% po-
lar residues (Figure 1), but when 410 different amino
acid sequences are simultaneously considered, all in-
terhelical contacts within theα-bundle are ‘labeled’
by polar side-chains forming intramolecular H-bonds,
usually in a group of related receptors. Displacement
of α-helices from their correct positions breaks some
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Figure 1. ‘Saturation of H-bond potential’ of polar residues in theµ-opioid receptor model. The color indicates residue type: white, aliphatic
(Ala, Pro, Val, Leu, Ile); green, aromatic (Phe, Tyr, Trp); magenta, sulfur-containing (Cys, Met); yellow, polar (Ser, Thr, Asn, Gln);
red, acidic (Asp, Glu); blue, basic (Lys, Arg). Theµ-selective agonist (−)morphine is shown in orange. H-bonds are indicated by dashed
lines. H-bonds with deviations from standard donor–acceptor distances>0.3 Å, H-bonds formed by Cys and Nε atoms of His residues, and
main-chain–side-chain H-bonds are not shown. The residue numbers correspond to theµ-opioid receptor sequence.
H-bonds, producing unpaired polar side-chains within
the lipid bilayer in tens or hundreds of GPCRs.
We have tested the ‘average’ atomic structure of
theα-bundle by using it as a template to calculate the
transmembrane domains of 26 different GPCRs from
eight remotely related subfamilies: vertebrate and in-
vertebrate opsins, cationic amine, melatonin, opioid,
chemokine, purine, and glycoprotein hormone recep-
tors (Table 1, Figure 2). The models were generated
by distance geometry using the H-bonds applicable
for each specific protein (Figure 1), while using the
‘average’ transmembrane structure to restrain the spa-
tial positions of the helices. In addition, we have
calculated the transmembrane domains of Duffy ery-
throcyte antigen and squid retinochrome, two proteins
that have detectable sequence homology with GPCRs,
but perform different functions: retinochrome restores
the pool of 11-cisretinal in some invertebrates through
all-trans→11-cis photoisomerization [20], while the
Duffy erythrocyte antigen serves as a ‘sink’ for various
chemokines [21]. Thus, both proteins share common
ligands with their GPCR counterparts, rhodopsins and
chemokine receptors, respectively. The models of
opsins, cationic amine, melatonin, opioid, and purine
receptors and retinochrome were tested for comple-
mentarity to the corresponding small, rigid ligands
shown in Table 1. It must be emphasized that the
models of different GPCRs are not completely iden-
tical. Changes in side-chain volumes and interhelical
H-bonds cause some shifts of entire helices and small
variations in their tilts and curvatures. Sometimes, the
appearance of a proline residue, usually close to the
extracellular side of theα-bundle, induces additional
kinks in the helices. Moreover, the conformations of
homologous side-chains can vary in different receptors
to provide optimum packing. These differences be-
tween the various GPCRs considered, clearly revealed
in the iterative distance geometry approach, would not
be reproduced by standard ‘modeling by homology’
procedures.
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Figure 2. Alignment of amino acid sequences of bovine, red cone, and crayfish opsins,µ-, δ-, and κ-opioid, interleukin-8A,
lutropin/choriogonadotropin hormone,β2- andα2A-adrenergic, D2A dopamine, 5HT1A serotonin, H2 histamine, m1 muscarinic receptors,
squid retinochrome, and Duffy erythrocyte antigen (sequence identifiers are shown in Table 1). The string of asterisks above each transmem-
brane helix (TMH) indicates the 26-residue transmembrane segments identified by Baldwin [5] and used for ‘generic’ numbering. In this
numbering system, V:3, as an example, designates the third residue of the 26-residue TMH V segment defined by Baldwin. As indicated in
the figure, the transmembrane segments determined in our studies typically are longer. All Arabic numbers listed correspond to the individual
sequences. N- and C-terminal segments and intracellular loops are omitted. Alignments of TMH I of squid retinochrome and TMHs I, II, III,
and V of Duffy antigen were obtained during distance geometry calculations of their transmembrane domains to satisfy the H-bond potential
of the polar residues in the helices. Alignment of the extracellular loop sequences was done using the ends of the transmembrane helices and





Driving forces of GPCR folding
Clustering of groups with similar polarities and
formation of H-bonds
The most general feature of protein structure is the
formation of clusters of groups with similar polari-
ties, which can be arbitrarily divided into highly polar
(hydroxyl, peptide groups, etc.), intermediate polar-
ity (sulfur-containing and aromatic), and nonpolar
(aliphatic) groups. The formation of such clusters is
energetically favorable, since chemically similar com-
pounds are more soluble in each other. The tendency
of nonpolar residues in proteins to be shielded from
water (and therefore to be clustered together in the hy-
drophobic core), which is usually treated as the main
principle of protein structure [22], or the major driving
force of protein folding [23], can be considered to be a
specific case of this more general ‘clustering by polar-
ity’ rule, which governs protein folding, protein–lipid
interactions (as discussed below), and the formation of
bilayers and micelles.
In proteins, clustering by polarity appears, first
of all, as hydrogen bonding of the polar back-
bone (∼−1.3 kcal/mol per H-bond in anα-helix
[24]) and formation of hydrogen bonds between side-
chains (up to−0.5 kcal/mol per H-bond between
two flexible side-chains in water [25,26]). A strik-
ing example of clustering by polarity is the spa-
tial distribution of 43 conserved GPCR residues that
form a continuous ‘minicore’ inside theα-bundle
composed of several layers with different polarities.
The first layer, in the middle of the transmem-
brane domain (Figure 3), consists mainly of polar
H-bonded residues that connect helices I, II, III,
and VII (Asn55(I:18), Asp83(II:14), Ser124(III:14),
Asn298(VII:13), Ser299(VII:14), Asn302(VII:17), and
Tyr306(VII:21)) and helices II and IV (Asn78(II:4)
. . . Trp161(IV:11)). In different receptors, this H-
bond network can be extended by additional po-
lar residues in positions I:17, II:11, II:15, II:17,
II:18, III:10, VII:15 (for example, in red cone
opsin, these additional residues are Thr70(I:17),
Glu102(II:17), Thr103(II:18), and Cys136(III:10)). The
next layer, closer to the intracellular side, con-
sists of 13 tightly packed, nonpolar aliphatic side-
chains from all seven helices (Figure 3). The
third layer consists of two clusters of polar side-
chains at the intracellular surface of the recep-
tor – Asn73(II:4)-Asn310(VII:25) and Ser132(III:22)-
Glu134(II:24)-Arg135(III:25)-Tyr136(III:26)-Tyr233(V:
22) (at the bottom of Figure 3). At the opposite,
extracellular side of the receptor, the cluster of aro-
matic and sulfur-containing residues (Phe212(V:11)-
Phe261(VI:12)-Cys264(VI:15)-Trp265(VI:16)-Tyr268(V
I:19)-Phe294(VII:9)) and two residues conserved
within subfamilies of GPCRs (for example, Met44(I:7),
Lys296(VII:11) in opsins) form a layer near the ligand-
binding pocket.
A number of additional polar clusters appear only
in small groups of GPCRs. For example, the H-bonded
Glu122-His211 (III:12-V:10) pair is present only in ver-
tebrate rhodopsins (Figure 4). The spatial distribution
of various groups around this pair has the appearance
of a polarity or solubility gradient, in which the most
polar residues are shielded from nonpolar aliphatic
ones by a shell of aromatic and sulfur-containing
side-chains.
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Figure 3. The evolutionarily conserved domain of GPCRs, depicted as the bovine rhodopsin structure with six residues replaced by more
conserved ones (I56G, T58V, A124S, A132S, S298N, and A299S). The set of 43 conserved residues was identified from the analysis of
sequence alignments of several GPCR subfamilies [16]. Colors are as in Figure 1. H-bonds are indicated by dashed lines. Residue numbers
correspond to the bovine rhodopsin sequence.
Figure 4. The Glu122-His211 pair and its surroundings in bovine rhodopsin. Colors are as in Figure 1. H-bonds are indicated by dashed lines.
Residue numbers correspond to the bovine rhodopsin sequence.
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Figure 5. Spatial arrangement of aromatic (Phe, Tyr, Trp, and His) residues in the bovine rhodopsin model. The residues are classified as buried
within the transmembraneα-bundle (orange), exposed to the lipid acyl chains (green), and exposed to the interfacial area of the bilayer, formed
by lipid head groups (magenta). Residue numbers correspond to the bovine rhodopsin sequence.
Figure 6. An example of correlated replacements of nonpolar residues in bovine (blue) and crayfish (red) rhodopsins. Residue numbers of both
receptors are indicated.
The GPCR models also form spectacular clusters
of aromatic side-chains, which can be found either at
the outer (lipid-facing) surface or buried within the
transmembrane domain (Figure 5). The lipid-facing
Phe 45, 52, 56, 85, 88, 115, 116, and Trp161 residues
at the external surfaces of helices I, II, III, and IV
in bovine rhodopsin fit together as pieces of a jig-
saw puzzle, creating a continuous sheet of closely
packed aromatic side-chains (Figure 5). At the same
time, helices III, IV, V, VI, and VII are linked together
through a ribbon of lipid-inaccessible, interacting aro-
matic side-chains of Trp126, Tyr206, Phe208, His211,
Phe212, Tyr261, and Trp265 (Figure 5, a part of this rib-
bon is also seen in Figure 4). In bovine rhodopsin, the
side-chains of Tyr43, Tyr206, Tyr301, and Trp161 face
the lipid environment, but their polar groups form H-
bonds either with main-chain carbonyls (all three ty-
rosines) or with other polar side-chains (Asn78-Trp161
pair).
‘Solubility forces’ are equally important for
protein–lipid interactions. For example, the lipid-
facing aromatic clusters (Figure 5) may increase the
solubility of rhodopsin in photoreceptor membranes,
which have an unusually high content of lipids with
unsaturated fatty acids [27]. The protein–lipid inter-
actions cause anisotropy of polarity of two different
types. First, the interior of GPCRs is more polar
than their lipid-facing surfaces (Figures 1, 3 and 4),
as is normally observed inα-helical transmembrane
proteins [28]. Secondly, the polarities of the lipid-
facing side-chains have an anisotropic distribution in
the direction perpendicular to the membrane plane to
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match nonpolar tails and polar head groups of lipids.
For example, the lipid-facing surface of the trans-
membraneα-bundle in bovine rhodopsin consists of
aliphatic and Phe residues in the middle of the bi-
layer, and weakly polar aromatic Tyr, Trp, and His
residues closer to the interfacial area (Figure 5). Sim-
ilar, layer-like, anisotropic distributions of side-chains
with different polarities are found in all structures of
transmembrane proteins, includingα-bundles of bac-
terial photoreaction centers [29], bacteriorhodopsin
[30,31], sodium channels [32], cytochrome c oxi-
dase [33], cytochrome b/c1 complex [34],β-barrels
of porins [35] and maltoporin, and right-handedπ-
helices (head-to-head dimers) of gramicidin A [36].
The interfacial region is especially abundant in Trp
residues. The solubility of 3-methyl-indole, the struc-
tural equivalent of the Trp side-chain, is significantly
higher in the interfacial region of membranes than
in water or in cyclohexane (which approximates the
membrane core) [37,38]. Remarkably, the entire struc-
ture of gramicidin A depends on such solubility ef-
fects: in isotropic organic solvents, this peptide forms
various doubleπ-helices with uniformly distributed
Val and Trp residues at the surface [39], instead of the
head-to-head dimers observed in micelles, in which
the Trp side-chains are concentrated at the ends of the
π-helix, at the water–detergent interface.
Side-chain packing
The geometrical packing of side-chains is another
factor that is important for the stability of proteins
[40]. All of our calculated GPCR structures are tightly
packed except for a few cavities, formed mostly by
polar groups, that can be filled by water, sodium
ion, or ligands. The close packing of side-chains
leads to correlated replacements of residues in order
to preserve the structural integrity of the transmem-
brane core. The appearance of a bulky (especially
aromatic) side-chain in the core usually requires a
concomitant decrease of volume in several surround-
ing side-chains. For example, the appearance of the
Phe78 side-chain in crayfish rhodopsin, in place of
Thr62(I:25), present in bovine rhodopsin, is correlated
with Leu76→Val91(II:7) and Ile307→Ala322(VII:22)
replacements (Figure 6). Occasionally, one aromatic
side-chain spatially substitutes for another, even if
their sequence positions differ. For example, Tyr(I:7),
present in most peptide GPCRs, is spatially substituted
by Trp(VII:8) in most cationic amine receptors. Com-
parison of any two remotely related GPCRs reveals
a multitude of such correlated replacements through-
out the transmembrane core. This topic is considered
further below.
Covalent cross-linking
The calculation of the ‘average’ structure of the trans-
membrane domain presented the opportunity to ex-
plore the formation of disulfide bonds in the GPCR
family. This was done by searching for pairs of suffi-
ciently close cysteines in all 410 GPCRs considered,
using the program ADJUST [16]. As a result, 16 dif-
ferent pairs of spatially proximate cysteines, which
collectively are present in 103 different GPCRs, were
detected (Table 2). All these pairs can have mutual
orientations of Cys side-chains appropriate for the for-
mation of disulfide bonds. As shown by site-directed
mutagenesis, all spatially close cysteine pairs form
disulfide bonds in proteins, even when inappropriately
arranged [41,42]. Thus, each of the 16 cysteine pairs
detected can be expected to form a disulfide bond
when present in GPCRs. To determine whether the
disulfide bonds are mutually compatible, all 16 pu-
tative disulfides were simultaneously included in the
calculations of the average model as supplementary
constraints. This increased the structural compactness
of theα-bundle without causing violations of the other
constraints. Some of the proposed disulfide bonds
were tested further by incorporating them into models
of specific GPCRs, such as Cys228-Cys278 (V:12-
VI:13) in red cone opsin, Cys117-Cys201 (III:11-V:7)
in the α2-adrenergic receptor, Cys130-Cys157 (III:20-
IV:7) in the IL-8A receptor and similar cysteines
in the IL-8B receptor, Cys138-Cys184 (III:12-IV:18)
in crayfish rhodopsin, Cys132-Cys217 (III:26-V:21) in
the ATP P2U receptor and the corresponding Cys135-
Cys216 (III:26-V:21) cysteine pair in a chemokine
receptor fromHerpesvirus saimiri, and Cys95-Cys310
(II:1-VII:25) in Duffy antigen. Again, these disulfide
bonds were found to be consistent with all the other
constraints in the specific GPCRs.
Interestingly, two opsins (X65877, P28678), three
melanocortin receptors (B46647, P33033, P32244),
and one high-affinity interleukin-8 receptor (P25024)
have one cysteine in helix III (in position III:12,
III:16, or III:20) and two proximal cysteines in he-
lix IV (IV:17 and IV:18, IV:13 and IV:14, or IV:7
and IV:10, respectively). In these cases, the Cys
from helix III can form a disulfide bond with either
of the two corresponding cysteines from helix IV.
The Cys(III:12)-Cys(IV:18), Cys(III:16)-Cys(IV:14),
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Table 2. Proposed interhelical disulfide bonds in the transmembrane domain of
GPCRs
Pairs of residues Types and number of receptors
I:14-VII:15 2 opsins
II:16-III:6 3 opsins
II:18-VII:15 3 opsins, 3 cholecystokinin, 3 C5a anaphylatoxin receptors
II:21-VII:8 1 angiotensin II, 1 galanin receptor
III:8-V:6 7 melanocortin receptors
III:11-V:7 9 α2-adrenergic receptors
III:12-IV:17 2 opsins
III:12-IV:18 4 opsins
III:16-IV:13 5 bradykinin, 3 melanocortin receptors
III:16-IV:14 11 melanocortin receptors
III:19-V:17 5 endothelin receptors
III:20-IV:7 17 angiotensin, 8 high-affinity interleukin-8 receptors
III:20-IV:10 1 high-affinity interleukin-8 receptor
III:26-V:21 2 oxytocin, 6 FMLP-related receptors
IV:18-V:10 4 cone opsins
V:11-VI:13 10 cone opsins
and Cys(III:20)-Cys(IV:7) disulfide bonds are more
consistent with other constraints incorporated in the
‘average’ model. However, the alternative disulfide
bonds can be formed by thiol–disulfide exchange, if
the position of helix III relative to helix IV changes
slightly, for example during activation of these recep-
tors. This hypothesis can be experimentally tested by
mutagenesis.
Another interesting feature of the detected disul-
fide bonds relates to their spatial locations in the
α-bundle. Most of the disulfides appear in regions of
the transmembrane domain that have a relatively small
number of interhelical H-bonds, i.e. between helices
III and IV, III and V, and V and VI. Apparently, these
disulfide bonds serve to stabilize theα-bundle when
other structure-stabilizing factors, such as interhelical
H-bonds, are insufficient.
Metal-binding clusters formed by Cys and His
residues [43] represent another type of natural cross-
link in proteins. A search for such clusters in the
410 sequences examined reveals that only squid
retinochrome has four spatially close residues in the
transmembrane domain – His18(I:0), His74(II:24),
His264(VII:0) and His268(VII:4) – that have the tetra-
hedral geometry appropriate to form a Zn2+-binding
site (Figure 7C). The formation of the Zn2+-binding
site is facilitated by the appearance of an additional
proline residue, Pro271(VII:7), in retinochrome, which
disrupts the N-terminal part of helix VII, allowing
the formation of a short 310-helix (the appearance
of a 310-helix is usually observed between two his-
tidines, in thei and i +4 positions of anα-helix,
that form a metal-binding site, as, for example, in
Zn-fingers (PDB file: 1zaa)). The formation of a
metal-binding cluster may be related to the unusually
short N-terminus in retinochrome (14 residues, com-
pared with 33 residues in bovine rhodopsin), which
may be insufficient to stabilize the receptor structure
in the region near the extracellular ends of helices I,
II, and VII. Therefore, the metal-binding center may
play a structure-stabilizing role. Moreover, one of
these histidines (His268(VII:4)) forms an H-bond with
Asp71(II:21), a counterion of the protonated all-trans
retinal Schiff’s base (SB) in the retinochrome model
(see below). Thus, metal binding to the histidine clus-
ter may contribute to regulation of spectral tuning of
the pigment, retinal photoisomerization, or hydrolysis
of the SB.
Evolution of GPCR structures
Relatedness of GPCRs and bacterial light-sensitive
proteins
The experimental structure of bacteriorhodopsin (PDB
file: 2brd, Reference 31) and our independently de-
rived rhodopsin model (PDB file: 1boj) differ in
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Figure 7. Binding pockets of 11-cis retinal in bovine rhodopsin (A), 3-hydroxy-11-cis retinal in crayfish rhodopsin (B), and all-trans retinal in
squid retinochrome (C). Colors are as in Figure 1. A possible bound water molecule near the PSB in bovine rhodopsin is shown as a dotted red
sphere in (A). Ligands are shown in orange.
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Figure 7. (continued).
Figure 8. Superposition of the bovine rhodopsin model with bound all-tr ns retinal (PDB file: 1boj, blue) and the bacteriorhodopsin structure
(PDB file: 2brd, Reference 31, red). Selected residues surrounding all-transretinal are shown. The Cα atoms of helical segments 12–33, 41–61,
84–104, 108–123, 139–156, 167–187, and 207–227 of bacteriorhodopsin were superimposed with segments 36–57, 78–98, 112–132, 161–176,
202–219, 250–270, and 287–307 of bovine rhodopsin, respectively.
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the positions of helices IV and V and in the tilts
of helices II and III, consistent with EM data (Fig-
ure 8). Nonetheless, the optimum superposition of
metarhodopsin II (complex with all-trans retinal) and
bacteriorhodopsin models gives only a 2.9 Å rmsd
for 140 common Cα atoms from all seven helices
(Figure 8). Remarkably, this optimum superposi-
tion of Cα atoms simultaneously yields an excellent
overlap of the retinylidene chromophore groups and
the binding pockets in both proteins. Seven iden-
tical, or similar, functionally important residues in
the retinal-binding pockets of rhodopsin and bacte-
riorhodopsin occupy spatially close positions (Fig-
ure 8): Lys296(VII:11) and Lys216 which form the
retinal SB; Glu113(III:3) and Asp85 counterions of the
SB; Met44(I:7) and Met20 (whose Sδ atoms contact
with the imine group of the SB); Thr118(III:8) and
Thr90; Trp265(VI:16) and Trp182; Tyr268(VI:19) and
Tyr185; and Ala295(VII:10) and Ala215. All these bind-
ing pocket residues are conserved in eukaryotic and
bacterial photopigments, except for Met44, Glu113,
and Thr118 of bovine rhodopsin (which are replaced
in invertebrate rhodopsins) and Met20 and Asp85 of
bacteriorhodopsin (which are replaced in bacterial
halorhodopsins). The second acidic residue near the
protonated SB in bacteriorhodopsin, Asp212, is re-
placed by Ala292(VII:7) in rhodopsin; the correspond-
ing A292D (or A292E) replacement has been found in
patients with congenital night blindness [44].
Other similar side-chains also spatially substi-
tute for each other in the retinal-binding pocket,
even though they come from different positions
in the amino acid sequences. The side-chains of
Phe293(VII:8) and Tyr57(II:25), of Phe276(VI:27) and
Trp189(VI:23, one turn apart), and of Phe287(VII:2)
and Phe206(VII:1, adjacent position) from rhodopsin
and bacteriorhodopsin, respectively, spatially overlap
and interact with the same groups of retinal. It is also
noteworthy that Asp115 (helix IV), which is conserved
in the bacteriorhodopsin family, spatially substitutes
for Glu122 (helix III) which is near theβ-ionone ring
of 11-cisretinal in rhodopsin. The relatedness of these
eukaryotic and bacterial light-sensitive proteins is not
detectable from a comparison of their amino acid se-
quences [45] and can only be seen after superposition
of their 3D structures, as is often observed for re-
motely related proteins with the same 3D folds and
chemically similar ligands [46,47].
Coordinated replacements within the transmembrane
domain
It is known that spatially proximate residues undergo
coordinated changes in homologous protein families
or, in other words, have similar ‘conservation pat-
terns’ [48]. A comparison of receptor models from
Table 1 reveals many such correlated replacements.
The correlations arise when a residue significantly
changes volume or polarity, which requires the con-
comitant replacement of several surrounding residues
to maintain the structural integrity of the transmem-
brane core. The correlations usually are not pair-
wise, as is often assumed [49–52], but rather involve
coordinated changes of groups of three and more
residues, as in Figure 7, which was discussed above.
Another interesting example of coordinated replace-
ment is the appearance of a group of polar residues
(Asn513(V:11), Asp556(VI:12), Met560(VI:16) and
Tyr/His590(VII:10)) in the lutropin/choriogonadotro-
pin receptor and other glycoprotein hormone re-
ceptors, in place of a ‘sulfur–aromatic’ clus-
ter, Phe222(V:11), Phe270(VI:12), Trp274(VI:16) and
Gly307(VII:10), present in most GPCRs (Figure 9). In
glycoprotein hormone receptors, these polar residues
form a network of H-bonds between helices V and VI
that augments the conserved polar cluster of Asp II:14,
Ser III:14, Asn VII:13, Asn VII:17, and Tyr VII:21
residues, which was described above.
The evolutionarily conserved domain of GPCRs
An additional example of ‘coordinated behavior’ in
the GPCR family can be seen in the spatial arrange-
ment of 43 evolutionarily conserved residues, which
form a single continuous domain in the intracellu-
lar half of the α-bundle (Figure 3). Some of these
residues are important for maintaining the appropri-
ate structure of the 7-α bundle, while others partic-
ipate in signal transduction and/or form a regula-
tory sodium-binding site, which is present in many
GPCRs [16]. The conserved residues II:14, III:14,
III:24, III:25, V:22, VI:12, VI:16, VII:17, and
VII:21 are involved in signal transduction, as iden-
tified by site-directed mutagenesis [53–63]. These
conserved residues form a continuous path in our
model of the transmembrane domain, starting from
Phe261(VI:12) and Trp265(VI:16) situated at the bot-
tom of the binding cavity, passing through the clus-
ter of Asp83(II:14), Ser124(III:14) and Asn302(VII:17)
residues in the middle of the membrane, and ending
at the Asp/Glu134(III:24), Arg135(III:25), Tyr223(V:22)
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and Tyr306(VII:21) residues situated at the intracel-
lular surface of theα-bundle. In the GPCR models,
two conserved tyrosine residues (V:22 and VII:21) can
form H-bonds either with residues from the central po-
lar (as in Figure 3), or with residues at the intracellular
surface (as in Figure 1), depending on their side-chain
conformers. We have previously suggested that rota-
tion of these tyrosines may occur during activation of
GPCRs [16].
In the GPCR models, the largest cluster of con-
served polar residues contains an empty space that
can be filled by water or by a sodium ion coordinated
with oxygens of the Asp95(II:14), Asn131(III:10),
Ser135(III:14), Ser311(VII:14) and Asn314(VII:17)
side-chains, known to be involved in signal transduc-
tion [54,57,64–66] (Figure 10). The importance of
Asp95(II:14) for Na+ binding has been shown by site-
directed mutagenesis [55,67–70]. Remarkably, the cy-
toplasmic part of the proton-transfer pathway in bac-
teriorhodopsin (near Thr46(II:14), Asp96(III:14) and
Phe219(VII:14)) spatially coincides with the sodium-
binding site of GPCRs after the superposition of
rhodopsin and bacteriorhodopsin structures [16].
Structural similarities of extracellular loops
Although the transmembrane 7-α-helical domain
plays a key role in ligand recognition and transduction,
the importance of the extracellular loops for folding,
ligand binding, and activation has also been demon-
strated for many GPCRs, including amine receptors,
opsins, ‘peptide’ (neurokinin, angiotensin, etc.), and
‘protein’ (chemokine, glycoprotein hormone) recep-
tors [71–80]. The amino acid sequences and lengths
of the loops and the N-terminal fragment can vary
widely. Typically, extracellular loops 1 and 3 (EL-
1 and EL-3) are relatively short and merely connect
transmembrane helices, while the N-terminal segment
and EL-2 are significantly longer (Figures 1 and 2).
However, there are exceptions. For example, the N-
terminal fragment is very short in purine receptors and
EL-2 is truncated in melanocortin receptors, but is ex-
tremely long in a recently cloned orphan receptor [81].
Nevertheless, there are some clear indications of struc-
tural similarities of the loops, at least in some subfam-
ilies of GPCRs. For example, EL-1 contains a charac-
teristic conserved pattern, Gx(W/F)x(F/Y/L)GxxxC,
and EL-2 has a conserved cysteine residue that forms
a disulfide bond with a cysteine residue from the
N-terminus of helix III (III:0).
Our recent attempts to model the three extracellu-
lar loops of opioid receptors [17] and red cone opsin
(unpublished) indicate that corresponding loops form
very similar structures throughout this set of receptors,
despite low sequence identity and some differences in
loop lengths in the opsin and opioid receptor subfami-
lies (Figure 2). Modeling of the loops was done using
a modified version of the iterative distance geometry
refinement employed for the transmembrane domain,
but including a more precise identification of regular
secondary structure based on analysis of hydrophobic-
ity and variability patterns, correlations in sequence
alignments, and maximization of the number of H-
bonds and hydrophobic contacts in the loops. For
example, the formation of aβ-hairpin by the second
extracellular loop, between helices IV and V (Fig-
ure 11), in all opioid receptors and vertebrate opsins
can be inferred from a consistent (i, i + 2) pattern
of polar residues in positions 214 and 216 (µ-opioid
receptor numbering) and in positions 220 and 222,
and nonpolar residues in positions 215, 219 and 221.
These side-chains are segregated into polar and non-
polar clusters on the opposite sides of theβ-hairpin.
Moreover, analysis of multiple sequence alignments of
GPCRs shows that there are correlated replacements
of residues that are in register in thisβ-hairpin. Since
theβ-turn in theβ-hairpin consists of an odd number
of residues, the only possible standard type ofβ-turn is
a type I with G1β-bulge, orαRγRαL motif [82]. This
motif is very common in proteinβ-hairpins [82], and
has been shown to be independently stable in aque-
ous solution [83] because, unlike the standard type I
and II β-turns, theαRγRαL turn is consistent with the
direction of twist inβ-structure [84]. In theµ-opioid
receptor structure, this turn is additionally stabilized
by H-bonds formed by the COO− group of Asp216
with the main-chain NH group of Thr218, and between
side-chains of Thr218 and Thr220 (Figure 11).
In the calculated structures ofµ-, δ-, andκ-opioid
receptors and red cone opsin, theβ-hairpin formed by
EL-2 and two adjacent extracellular loops, EL-1 and
EL-3, create an almost continuous, compact structure
(Figure 1). The structural compactness of the extra-
cellular domain, recently demonstrated by electron
cryomicroscopy [3], is consistent with the presence of
a disulfide bond connecting the N-terminus and EL-3
in chemokine, angiotensin, and endothelin receptors
[85,86], an additional, nonconserved disulfide bond
within EL-2 of β2-adrenergic receptors [78], and with
the simultaneous appearance of cysteine pairs (which
probably form disulfides) in some extracellular GPCR
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Figure 9. A coordinated replacement of an ‘aromatic cluster’ present in most GPCRs (A, residues of theδ- pioid receptor are shown) by a polar
cluster present only in the glycoprotein hormone receptor subfamily (B, the same residues of lutropin/choriogonadotropin hormone receptor
are shown in the same projection). Colors are as in Figure 1. H-bonds are indicated by dashed lines.
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Figure 10. The possible structure of the Na+-binding center in theδ-opioid receptor. Residues are colored by element, the Na+ ion is shown
as a dotted purple sphere and the tentative water molecule as a dotted red sphere. H-bonds are indicated by dashed lines.
Figure 11. A tentative structure of the second extracellular loop in theµ-opioid receptor, connecting helices IV and V and linked to helix III
by a disulfide bond. Residues are colored by element. H-bonds are indicated by dashed lines.
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regions, for example, in the N-terminal fragment ofµ-
andκ-opioid receptors and within EL-1 and EL-3 of
purine receptors.
Theβ-hairpin formed by EL-2 is of special interest.
This loop is visible as an elongated, poorly resolved
feature in the extracellular part of the 3D EM map
of frog rhodopsin [3]. Thisβ-hairpin probably forms
an independently stable structure, since antibodies de-
veloped against peptide fragments representing EL-2
of several GPCRs recognize the entire receptors and
interfere with ligand binding and/or cAMP accumula-
tion [77,87–89]. Moreover, EL-2 may also participate
in the activation process, since some GPCRs can be
activated by modifications within EL-2 [77] or by anti-
body binding to the EL-2 region [88,90–93]. In human
red opsin, His197 and Lys200 from EL-2 are involved
in spectral tuning of pigments by Cl− [94]. Thus, this
β-hairpin is probably an important structural and func-
tional element that participates in both ligand binding
and activation in most GPCRs.
Interestingly, a similarβ-hairpin has recently been
determined in bacteriorhodopsin by high-resolution
electron cryomicroscopy [95]. In bacteriorhodopsin,
this β-hairpin occupies the same spatial position as
in our rhodopsin model, although it is formed by
a different extracellular loop: EL-1 instead of EL-
2 as in GPCRs. In bacteriorhodopsin, thisβ-hairpin
also plays a functionally important role as part of the
proton-transfer pathway [95].
Coevolution of ligands and their binding pockets
The individual GPCR models were constructed solely
from H-bonding constraints, using no information
about the receptor ligands. Nevertheless, each model
has only one large cavity that can be occupied by lig-
ands (Figures 12–17). In the models of rhodopsins,
retinochrome, opioid, melatonin, purine, and cationic
amine receptors, the cavities are situated in the same
region of the transmembrane domain, between helices
II-VII, and are partially covered by extracellular loops.
The bottom of the binding pockets corresponds
to the extracellular boundary of the evolutionar-
ily conserved domain of GPCRs (Phe212(V:11),
Phe261(VI:12), Cys264(VI:15), Trp265(VI:16), and
Ala295(VII:10) in Figure 3). Therefore, there are some
clear structural similarities between different GPCRs
in this region. The ligand fragments positioned here,
i.e. the portion of retinal between the 9-methyl group
and theβ-ionone ring, Tyr1 of opioid peptides, the
adenine group of ATP, and the catechol moiety of
catecholamines, occupy very similar spatial positions
(Figure 12) and interact with the same residues. Some
of the residues at the bottom of the binding pocket are
conserved in most GPCRs, but are replaced in, for
example, glycoprotein hormone receptors (Figure 9).
Other residues in this region are conserved only in
subfamilies of GPCRs and are correlated with ligand
structure (for example, in positions III:7, V:7, VI:20,
VII:7, and VII:11 shown in Figure 12). The triad of
Met I:7, Glu III:3, and Lys VII:11, which interact
with the N+ of the protonated Schiff’s base (PSB) in
all vertebrate opsins (Figure 7A), is spatially replaced
by Trp VII:8, Asp III:7, and Tyr VII:11, respectively,
in all cationic amine receptors, where two of these
residues (Asp III:7 and Tyr VII:11) form the binding
site for the common N+ of cationic amines (Figures
14–16). This Asp III:7. . . Tyr VII:11 H-bonded pair is
also present in opioid receptors, where it, too, forms a
binding site for the ligand N+ (Figure 13).
Retinal-binding pocket The complementarity of the
binding cavities to their native and synthetic ligands is
evident from their geometrical fit, from the formation
of intermolecular H-bonds, and from the clustering of
receptor and ligand groups with similar polarities. For
example, in bovine rhodopsin, the N+ of the PSB oc-
cupies a polar site that is formed by the carboxylate
of Glu113(III:3) (the PSB counterion), the aromatic
ring of Phe293(VII:8), the backbone of helix II near
Gly90(II:21), the side-chain of Thr94(II:25), and by the
δ sulfur of Met44(I:17) (Figure 7A). The polyene chain
of 11-cis retinal passes through a narrow ‘gate’ (∼4 Å
wide) between helices III and VII, created by residues
with small side-chains (Ala117(III:7), Thr118(III:8),
Gly121(III:10), Ala292(VII:7), and Ala295(VII:10)).
Theβ-ionone ring occupies a wider (∼7.5 Å) nonpo-
lar cavity surrounded by Leu125(III:15), Phe208(V:7),
Phe212(V:11), Phe261(VI:12), Leu262(VI:13), Cys264
(VI:15), Trp265(VI:16), and Phe294(VII:9). Thus,
the polarities of residues in the binding pocket of
rhodopsin match the polarities of contacting retinal
groups: the charged PSB of retinal is surrounded
by polar side-chains, while the polyene chain and
β-ionone ring interact with nonpolar aliphatic and aro-
matic side-chains. In several invertebrate opsins, polar
residues also appear near theβ-ionone ring (Ser V:7
and Ser/Asp/Asn VI:23), allowing an H-bond with the
OH-group of 3-hydroxy retinal, the native ligand of
some invertebrate photopigments [96]. In the cray-
fish rhodopsin models, Ser222(V:7) forms an H-bond
with the 3-OH group of 3-hydroxy-11-cis retinal, i.e.
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in the inactive receptor state (see Figure 7B), while
Asn298(VI:23) can form an H-bond with the 3-OH
group of the shiftedβ-ionone ring in the all-trans
isomer, i.e. in the photoactivated receptor [16]. The
same Ser V:7 and Asn/His VI:23 residues are involved
in H-bonds with the catechol ring in adrenergic and
dopamine receptor models (Figure 14).
The structures of the binding pockets in various
GPCRs are adapted to different ligands by concerted
replacements among 20 residues, which transform
a nonpolar, narrow, elongated ‘cleft’ in opsins and
retinochrome (Figure 7) to ‘L-shaped’ binding pock-
ets containing many polar residues in opioid receptors
(Figure 13), or to smaller cavities, surrounded by
aromatic side-chains, in acetylcholine receptors. How-
ever, in cases where the ligand remains the same, the
structures of the binding pockets are generally simi-
lar, even if the sequence identity of the corresponding
GPCRs is low (Figure 7).
An example of remote GPCRs with the same lig-
and are vertebrate and invertebrate opsins, whose
sequence identity is∼25%. All opsins covalently bind
11-cis retinal via a PSB with Lys(VII:11) and convert
it to the all-trans isomer under illumination, which re-
sults in activation of the opsins. The binding pockets
of 11-cis retinal are very similar in bovine and cray-
fish rhodopsins, because many key residues in this
region are the same: Met I:7, Gly III:11, Trp IV:25,
Trp VII:16, Tyr VI:19, Phe VII:9, Ala VII:10,
Lys VII:11. However, a few replacements in cray-
fish rhodopsin shift theβ-ionone ring and the ad-
jacent segment of the polyene chain by∼2.5 Å
toward helix IV, while still maintaining a cavity
shape appropriate for binding 11-cis retinal. This is
structurally accomplished by correlated replacements
of Phe208(V:7)→Ser222 and Phe261(VI:12)→Trp287
(Figure 7), which simultaneously increases the vol-
ume of a side-chain in one part of the pocket, while
decreasing it in another, similar to the ‘repacking’
of side-chains in remotely related GPCRs (Figure 6).
The Ala117(III:7)→Gly133replacement also facilitates
the small shift of the polyene chain toward helix III,
while the bulky side-chain of Tyr309(VII:7), which ap-
pears in place of Ala292, covers the retinal polyene
chain from the extracellular side in crayfish rhodopsin
(Figure 7B). Tyr129(III:3) in crayfish rhodopsin sub-
stitutes for Glu133(III:3), the counterion of the PSB
in bovine rhodopsin. The side-chain of Tyr129(III:3)
is longer than that of Glu133(III:3) and its OH-group
can spatially substitute for the water molecule that H-
bonds with the PSB in the bovine rhodopsin model. A
cluster of five methionines (Met60(I:7), Met102(II:17),
Met103(II:18), Met106(II:21) and Met110(II:25)) sur-
rounds the aromatic side-chain of Tyr129(III:3) in cray-
fish rhodopsin, in place of Met44(I:7), Met86(II:17),
Val87(II:18), Gly90(II:21) and Thr94(II:25) in the
vicinity of Glu113(III:3) in bovine rhodopsin.
Squid retinochrome is an example of structural
adaptation to a different stereoisomer of the same
ligand (Figure 7C). This protein, found in some inver-
tebrates, preferentially binds all-trans retinal (instead
of the 11-cis isomer in rhodopsin) and transforms
it to 11-cis retinal through all-trans→11-cis photo-
isomerization, i.e. it functions in the direction op-
posite that of rhodopsin [23]. The structure of the
retinochrome ligand-binding cavity is very similar to
that in bovine rhodopsin (Figures 7A and C), with the
similarly located Lys271(VII:11) forming a PSB with
all-trans retinal. The preferential binding of the all-
trans isomer instead of 11-cis retinal is achieved by
coordinated replacements of several residues in the
binding pocket. Glu113(III:3), the counterion of the
PSB in rhodopsin, is replaced by Met93(III:3) and the
only negatively charged residue near Lys271(VII:11) is
Asp71(II:21) which probably serves as the counterion
for the shifted N+ group of the PSB in retinochrome.
In the E113Q(III:3)/G90D(II:21) rhodopsin double
mutant, the corresponding Asp90(II:21) residue can
function as an alternative counterion of the PSB [97].
This mutation confers constitutive activity to the re-
ceptor, the possible cause of congenital night blind-
ness in patients with G90D(II:21) mutant rhodopsin
[97]. In the retinochrome model, this Asp71(II:21)
residue forms H-bonds with theε-amino group of
Lys275(VII:11) and with His268(VII:4). Compared
with bovine rhodopsin, Ala(III:7)→Gly replacement
in retinochrome helps to adjust the 13-methyl group of
the all-transisomer between helices III and VII, while
Ile(V:4)→Phe and Ala(VI:20)→Gly substitutions ac-
commodate the shiftedβ-ionone ring. The coordi-
nated Thr(III:8)→Phe and Phe(V:7)→Ala replace-
ments move the phenylalanine aromatic ring from V:7
to III:8, i.e. closer to helix III, thus providing space for
the 9-methyl group of the all-trans isomer. The disap-
pearance of Pro VI:18 decreases the kink in helix VI
of retinochrome and shifts this helix closer to helix III.
As a result, theβ-ionone ring and the 9-methyl group
of 11-cis retinal in photoactivated retinochrome can-
not occupy the same position as in the complex with
rhodopsin, due to substantial hindrances with helices
III and VI. Therefore, after photoisomerization, 11-cis
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Figure 12. Overlap of several GPCR agonists after superposition of their receptor models: all-trans retinal in metarhodopsin II (red), JOM-13
(Tyr-c[D-Cys-Phe-D-Pen]) in theδ-opioid receptor (green), and epinephrine in theβ2-adrenoreceptor (light and dark blue). Epinephrine is
shown in two possible orientations, ‘upper’ (light blue) and ‘lower’ (dark blue). Several selected residues from the binding pockets are shown
by thin lines.
Figure 13. JOM-13 (Tyr-c[D-Cys-Phe-D-Pen]) (magenta) in the binding pocket of theδ-opioid receptor. Residues are colored by element.
H-bonds are indicated by dashed lines.
retinal moves toward the extracellular surface and can
be released from the binding pocket.
Opioid receptors In opioid receptors (Figure 13), the
binding cavity is significantly changed, compared to
that in rhodopsin. The binding site of the N+ group of
the retinal PSB between helices II and VII is absent
in opioid receptors, with this space now filled by the
more bulky residues Tyr I:7, Leu II:21, Tyr II:28, and
His/Tyr VII:4. On the other hand, the space between
helices III-VII is expanded by Trp(IV:25)→Ala and
Tyr(VI:19)→Ile replacements. As a result, the size
and shape of the cavity are altered. Furthermore, many
residues in the cavity are more polar in the opioid re-
ceptors and can form numerous H-bonds with various
opioid ligands [17]. The polar residues of opioid re-
ceptors in this region are Gln II:24, Asp III:7, Tyr III:8,
Asp/Glu V:−1, Thr/Asn V:0, Lys V:3, His VI:20,
Thr VI:24, Lys/Glu VI:26, Thr VI:27, Tyr/Trp VII:3,
His/Tyr VII:4, and Tyr VII:11. The significance
of polar interactions involving Asp III:7, Tyr III:8,
His VI:20, and Tyr VII:11 has been demonstrated
by site-directed mutagenesis [98–101]. Asp III:7 and
His VI:20 residues in the bottom of the binding pocket
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Figure 14. Schematic representation of binding pockets for natural ligands in cationic amine receptors. H-bonds are indicated by dotted lines
and electrostatic interactions by dashed lines.
are of special importance, since they serve as two
‘attachment points’ for the N+ and OH groups, respec-
tively, of the tyramine moiety common to most opioid
ligands (Figure 13, Reference 17). The central, con-
formationally constrained fragments found in many
opioids (e.g. the disulfide-bridged cycles common to
several peptide ligands and various ring structures in
nonpeptide ligands) are oriented approximately per-
pendicular to the tyramine and are directed toward the
β-hairpin formed by EL- 2 (Figure 13).
Cationic amine receptors The family of cationic
amine receptors provides an especially good example
for verification of receptor models by ligand dock-
ing, since the native ligands for these receptors, i.e.
epinephrine, norepinephrine, dopamine, serotonin,
histamine, and acetylcholine, have different functional
polar groups that are ‘mirrored’ by corresponding re-
placements of amino acid residues surrounding the
ligands in the binding pockets (Figure 14). In gen-
eral, the shape of the ligand-binding pocket in cationic
amine receptors is similar to that in opioid receptors,
since in both subfamilies the space between helices
I, II, and VII, which forms part of the retinal-binding
site in rhodopsins, is filled by bulky side-chains from
positions II:24 (Phe, Trp, Leu), III:3 (Phe, Tyr, Trp),
and VII:8 (Trp). However, the cationic amine and opi-
oid receptors have different spatial arrangements of
aromatic and polar side-chains, except for the com-
mon Asp III:7 . . . Tyr VII:11 pair. In cationic amine
receptors, aromatic residues are conserved in positions
VI:19 (Phe/Tyr), VI:20 (Phe), and VII:3 (Phe/Tyr/Trp)
but are never present in position V:7 (Phe in all opi-
oid receptors). The characteristic set of polar residues
in the cationic amine subfamily includes Thr III:4,
Ser III:11, Thr/Asn III:12, Gln/His/Trp/Arg IV:25,
Asp/Ser/Thr V:6, Ser/Thr V:7, Asn/His/Tyr VI:23,
Glu/Lys/Asn/His/Tyr VII:3, Asn/Thr/Tyr VII:7,
Tyr/Trp VII:11, and Ser VII:14, while positions III:8,
V:3, and VI:20 are usually occupied by nonpolar
residues.
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The ligand-binding cavities of adrenergic, dopa-
mine, serotonin, and histamine receptors (Figures 14–
16) are rather similar in size and shape. The aromatic
(catechol, indole, or imidazole) rings of their native
ligands occupy a binding site formed by aliphatic and
aromatic-side chains: Val III:8, Val V:3, Val V:4,
Trp VI:16, Phe VI:12, and Phe VI:20, and by po-
lar residues in positions V:6 (Thr, Ser, Asp), V:7
(Thr, Ser), and VI:23 (Asn, His) that can H-bond
with polar groups in the rings. Replacement of the lig-
and aromatic ring by an acetyl group in acetylcholine
is correlated with a smaller binding cavity in mus-
carinic receptors, which results from the appearance
of bulky aromatic side-chains of Tyr III:8, Trp IV:18,
and Trp VII:3 (Figure 14). The Cα and Cβ atoms of
catechol ligands interact with Leu/Phe/Ile/Val VII:6,
Asn/Thr/Tyr/Phe/Leu/Val VII:7, and Phe/Tyr VII:3
residues. The common binding site of the amine ligand
N+ group provides a more polar environment, usually
consisting of Asp III:7 (the counterion of N+), the
moderately polar Cys/Ser III:11 (Val inβ-adrenergic
receptors), Gly VII:10, Tyr VII:11, Ser VII:14, and
Met/Val/Leu/Ile II:17.
Despite the similarities in the binding pockets, the
cationic amine ligands are oriented slightly differ-
ently in their receptor models. Two alternate spatial
positions of the ligands are possible, one that is com-
mon for β-adrenergic and dopamine receptors and
another that is characteristic ofα-adrenergic, sero-
tonin, and histamine receptors. In the alternate posi-
tions, the ligand is shifted in a direction parallel to
the membrane plane, similar to the shift of the reti-
nalβ-ionone ring in crayfish rhodopsin compared with
bovine rhodopsin (Figures 7A and B) or to the shift of
the Tyr1 of peptide ligands in theµ-opioid receptor
compared with theδ-receptor [17]. A comparison of
norepinephrine orientations inβ2- andα2-adrenergic
receptors is particularly informative (Figure 15). In
the first orientation, as in theβ2-receptor binding
site, the ligand catechol ring is positioned between
helices V and VI with themeta-OH group forming
an H-bond with Ser204(V:7) and thepara-OH group
with Asn293(VI:23). The formation of an H-bond be-
tween the ligandmeta-OH group and Ser204(V:7) in
theβ2-adrenergic receptor [102], and the involvement
of His VI:23 in interactions withpara-substituents of
similarly oriented ligands at the dopamine D2 recep-
tor [103] have been suggested from mutagenesis data.
Another serine from helix V, Ser203(V:6), participates
in the H-bond network between helices III, IV, and V
(Thr118(III:12)-Ser165(VI:18)-Ser203( V:6)) that may
stabilize the transmembraneα-bundle (see Figure 15).
These interactions of the Ser203(V:6) residue may ex-
plain the incorrect folding observed for S165A and
S203Aβ2-adrenergic receptor mutants [102]. N+ of
the ligand is positioned between helices III and VII
with additional space available to accommodate dif-
ferent N-substituents (methyl, ethyl, isopropyl groups,
etc.). Theβ-OH group of epinephrine forms an H-
bond with Asn312(VII:7) in β2-adrenergic receptors.
In α2-adrenergic receptors, the interaction of the
catechol ring with Phe411(VII:6) and Phe412(VII:7)
shifts the ligand to the second orientation, with the
N+ and β-OH group∼2.5 Å closer to helix II and
the catechol ring∼1.5 Å closer to helix IV. As a
result, themeta-OH group of norepinephrine forms
an H-bond with Ser200(V:6) (in place of the corre-
sponding interaction with Ser204(V:7) in β2-adrenergic
receptors) and the ligand aromatic ring approaches
Val114(III:8). This is consistent with mutagenesis data
obtained from replacement of Ser200(V:6) in α2- [104]
and the corresponding Ser188(V:6) in α1-adrenergic re-
ceptors [105]. The ligandpara-OH group can H-bond
either with the main-chain carbonyl of residue V:3 or
with the polar side-chain present in someα-receptors
in position V:7. Because of the shift of the ligand N+
toward helix II of theα2-receptor, theβ-OH group of
norepinephrine forms an H-bond with Asp113(III:7)
(instead of Asn312(VII:7), as in β2-adrenergic re-
ceptors). Inα-adrenergic receptors, the unoccupied
space around the protonated amine decreases and
can accommodate only smallerN-methyl and N-
ethyl substituents [106]. In theα2-receptor model,
theα-methyl group of (S)(+)-α-methyldopamineoccu-
pies a small empty space between Phe411(VII:6) and
Gly415(VII:10) that forms the ‘third recognition site’
[106] in this receptor subtype. This site is absent in the
α1-adrenergic receptor subtype due to Phe VII:6→Leu
substitution.
Replacements of residues III:8, V:6, V:7, VI:23,
VII:3, and VII:7 in the binding pocket of cationic
amine receptors are clearly coordinated with ligand
structure (Figure 14). For example, the III:8 posi-
tion, occupied by nonpolar aliphatic residues in most
cationic amine GPCRs, is replaced by Tyr106(III:8)
in muscarinic receptors, where the Tyr OηH group
forms an H-bond with the acetylcholine acetyl group
(Figure 14). A similar appearance of Asn VI:23 and
His VI:23 residues inβ-adrenergic and dopamine re-
ceptors, respectively, provides H-bonds withpara-OH
groups of the ligand catechol rings. Asp V:6, present
only in histamine H2 receptors, can form an H-bond
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with Nτ of histamine, in agreement with mutagen-
esis data [107], and Glu VII:3 (a position occupied
by aromatic residues or Gly in other cationic amine
receptors) in the H2 receptor can interact electrosta-
tically with the ligand imidazole group. Asn VII:7
in β2-adrenergic and 5-HT1A receptors, which forms
an H-bond with theβ-OH group of epinephrine and
norepinephrine or with the 5-OH group of serotonin,
respectively (Figure 14), provides another example.
Asn VII:7 has been shown to play an important role
in the binding of theβ-receptor selective ligands pin-
dolol and propranolol, which possessβ-OH groups
[108,109]. It has been demonstrated that the human
5-HT1B serotonin receptor, with Thr355(VII:7) in this
position, binds pindolol and propranolol poorly, while
the T355N(VII:7) 5-HT1B mutant acquires high affin-
ity for these ligands [110]. The absence of aβ-hydroxy
group in dopamine is correlated with the replacement
of Asn VII:7 of β-adrenergic receptors by Thr or Val
residues in dopamine receptors. These residues cannot
form similar H-bonds with aβ-hydroxy substituent.
It should be emphasized that the binding pock-
ets of cationic amine receptors are generally larger
than many of their ligands. This leads to the possi-
bility of different arrangements of some ligands in the
binding pockets. For example, theβ2-adrenergic ago-
nists norepinephrine and isoproterenol can be inserted
in the β2-receptor model in two alternative orienta-
tions, differing primarily in the position of N+, which
can be arranged either below or above Asn312(VII:7)
(Figures 12 and 16). In the latter arrangement, N+
of the ligand is shifted from the bottom of the cav-
ity toward the extracellular surface by 5.2 Å (Fig-
ure 16). In the ‘lower’ arrangement, norepinephrine
is situated close to the position of the polyene chain
of retinal bound to rhodopsin, while in the ‘upper’
arrangement it is positioned like the Tyr1 portion of
peptide ligands bound to opioid receptors (Figure 12).
The same two alternate positions are also possible
for small ligands of other GPCRs, for example for
morphine in opioid receptors [17]. In the ‘lower’ posi-
tion, the N-isopropyl group of isoproterenol interacts
with Met82(II:17), Val117(III:11), Gly315(VII:10), and
Tyr316(VII:11), while in the ‘upper’ position it inter-
acts with Phe89(II:24), Thr110(III:4), His173(IV:25),
and Tyr308(VII:3). However, inboth positions of ei-
ther norepinephrine or isoproterenol, the N+ interacts
with the same Asp113(III:7) side-chain, theβ-hydroxy
group forms an H-bond with the same Asn312(VII:7)
side-chain, and the catechol ring occupies nearly
identical positions and interacts with the same
residues (Ile201(V:4), Trp286(VI:16), Phe290(VI:20),
and Leu311(VII:6)) and forms H-bonds between its
meta-OH andpara-OH substituents and Ser204(V:7)
and Asn293(VI:23), respectively (Figure 16).
All native cationic amine ligands described above
(Figures 14 and 15) were docked in the lower po-
sition, although in most cases the alternative upper
positions are also possible. Most larger, synthetic lig-
ands can be inserted in the binding pockets in only
one of these positions. For example, theβ-antagonist
carazolol can occupy only the lower position in the
binding pocket because of hindrances between its
ring system and residues from helix V in the up-
per ligand orientation. In contrast, theβ2-affinity
label [125I]iodoazidobenzylpindolol, which binds ir-
reversibly to theβ2-adrenergic receptor [111], can be
arranged only in the upper position. In theβ2-receptor
model, the azido group of this label can be cross-
linked to the Nε1 groups of either Trp330(VII:8) or
Trp109(III:3), depending on the rotamer of the phenyl
ring of the label (the corresponding N...N distances
are 3.0 and 3.5 Å, respectively). This agrees with
experimental data that implicate Trp330(VII:8) and an-
other unidentified residue between helices III and V
as two sites of covalent labeling by theβ2-affinity
reagent [111]. Similarly, some high-affinityα-receptor
agonists with bulky phenyl-containing N-substituents
[108] can be accommodated in the binding pocket only
in the upper position.
Comparison of GPCR models with experimental
data
The individual GPCR models are consistent with ex-
perimental data that were not considered in the cal-
culations and which can therefore be used for ver-
ification. The model of rhodopsin, for example, is
in agreement with a vast collection of published bio-
physical data, such as the arrangement ofα-helices in
the low-resolution 3D EM maps; mapping of water-
and lipid-accessible rhodopsin residues by chemical
probes; identification of residues surrounding retinal
by site-directed mutagenesis and cross-linking; orien-
tations of all-trans and 11-cis retinal relative to the
membrane plane and the distances from the ligand
to the intra- and extracellular surfaces, determined
by linear dichroism and fluorescence quenching; re-
constitution studies of opsin with synthetic retinal
analogues; the conformation and environment of the
PSB formed between Lys296(VII:11) and 11-cis reti-
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Figure 15. Different positions of norepinephrine in the binding pockets ofβ2 (red) andα2 (blue) adrenergic receptors. Selected residues from
the binding pockets are shown by thin lines and H-bonds are indicated by dashed lines.
Figure 16. ‘Upper’ (blue) and ‘lower’ (red) positions of norepinephrine in theβ2-adrenoreceptor binding pocket. Residues are colored by
element. H-bonds are indicated by dashed lines.
nal, studied by Raman, FTIR, and13C solid-state
NMR spectroscopies; compensatory replacements of
the Glu113(III:3) by Asp90(II:21) or Asp117(III:7)
residues, and many others [16]. The possibility of
H-bonds between pairs of polar residues (II:14 and
VII:17, II:28 and VII:3, and III:7 and VII:4) in the
model is also in agreement with constraints experi-
mentally derived from site-directed mutagenesis, such
as the proximity of Asn87(II:14) and Asn318(VII:17)
in the gonadotropin-releasing hormone receptor [66],
Asp120(II:14) and Asn396(VII:17) in the 5-HT2A re-
ceptor [65], Asp397(II:28) and Lys583(VII:3) in the
lutropin/choriogonadotropin hormone receptor [112],
and Asp125(III:7) and Lys331(VII:4) in α1B-adrenergic
receptors [113]. The model is also consistent with
the formation of artificial Zn2+-binding sites in the
NK-1 [114] andκ-opioid receptors [115] by histidines
present in positions V:−1, V:3, and VI:27 of mutant
receptors [16].
A comparison of our rhodopsin model and a re-
cently published EM-based Cα atom template [15]
shows that they are rather similar (Figure 17). The
observed 3.3 Å rmsd (for 169 common Cα atoms)
originates mostly from small outward shifts of TMH
II and the C-terminus of TMH III, and from∼3 Å
shifts of TMH V and TMH VI in the direction per-
pendicular to the membrane plane in the EM-based
model relative to ours. This can be partially attributed
to some errors in the EM-based model [15]. Since the
individual residues are not visible in the EM maps
(the resolution is 7.5 Å in the membrane plane and
16.5 Å in the perpendicular direction), the TMHs were
approximately positioned by translating and rotating
them to orient their most conserved residues within the
α-bundle and to align the most hydrophobic portions
of the helices in the normal to the membrane. As a
result, and as was discussed by Baldwin et al. [15],
this model contradicts some experimental data, such as
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Figure 17. Superposition of the bovine rhodopsin model calculated with H-bond constraints (PDB file: 1bok, blue) and the Cα a om template
obtained by fitting ideal helices to the 7.5 Å resolution EM map of frog rhodopsin (Reference 15, red). The Cα atoms of common residues in
the models (segments 38–64, 71–94, 111–141, 151–175, 204–223, 247–274, and 288–310) were superimposed (bovine rhodopsin sequence
numbering).
the formation of a Zn2+-binding cluster by histidines
incorporated into the extracellular ends of TMH V and
TMH VI [114,115] and site-directed mutagenesis re-
sults that reveal the spatial proximity of residues of
TMH III and TMH V that participate in the binding
of catecholamines [65,66,102,120–122]; the proxim-
ity of conserved Asp and Asn residues of TMH II and
TMH VII, respectively; and the proximity of Gly121
(TMH III) and Phe261 (TMH VI) in bovine rhodopsin
[123,124]. All these data are satisfied in our model.
On the other hand, some recent experimental data
suggest that our model may be flawed on the intra-
cellular side of the transmembraneα-bundle: TMH
V is probably longer and more tilted than in our
model and TMH VI may be shifted in the vertical
direction toward the intracellular surface to bring to-
gether histidine residues incorporated into the ends of
TMH III and TMH VI that can form a Zn2+-binding
cluster in rhodopsin mutants [117]. We are presently
investigating these alternatives.
As noted in the preceding sections, the vast ma-
jority of available mutagenesis data is in excellent
agreement with our models of cationic amine recep-
tors. The importance of aromatic residues Phe VI:20
in β-adrenergic and 5-HT2A receptors and residues
Tyr(III:8), Tyr(VI:20), Tyr(VII:7), Tyr(VII:11) in mus-
carinic receptors has been shown by Strader et al.
[125], Choudhary et al. [126,127], and Wess et
al. [122, 128]. The ‘key’ role of Asp(III:7) in the
binding of amines has been demonstrated by point
mutations ofβ2-adrenergic receptors [102,120,121],
α1B-adrenergic receptors [113],α2A-adrenergic re-
ceptors [104], m1 muscarinic receptors [129], hista-
mine receptors [130], dopamine receptors [131,132],
and 5-HT1A and 5-HT2 receptors [133,134]. It has
also been demonstrated that many polar residues
which form H-bonds with various cationic amine
ligands in our models are important for ligand
binding: Ser/Thr V:6, Ser/Thr/Asp V:7, Ser V:10
[102,104,105,107,122,128,135,136], Ser III:11 [137],
Tyr III:8, Tyr VI:19 [122,128], Asn VI:20 [138],
His VI:23 [103], Asn/Thr/Tyr VII:7 [108–110,122,
128], Tyr VII:11 [122,128], and Ser VII:14 [54].
The models are also consistent with the accessibilities
of residues from helices III, V, and VII to chemi-
cal modification by water-soluble probes, which were
determined by cysteine-scanning mutagenesis of the
dopamine D2 receptor [89,139,140]. In the D2 recep-
tor model, residues III:1, III:3, III:4, III:7, III:8, III:11,
V:3, V:4, V:6, V:7, V:8, V:11, VII:2, VII:3, VII:4,
VII:6, VII:7, VII:8, VII:10, and VII:11 are accessi-
ble to water because they are situated in the binding
pocket, consistent with the labeling data. A number
of other polar residues of dopamine receptors (III:14,
III:18, III:22, V:22, VII:13, VII:17, and VII:21) are
situated within theα-bundle in the model, where they
form extensive hydrophilic clusters and can be par-
tially hydrated. It has been shown that all these polar
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residues as well as several adjacent residues (III:15,
III:18, V:10, V:13, V:14, and VII:18) and a few
residues located close to the helix ends (III:2, V:2,
V:5, V:9, and VII:5) are also accessible for chemical
modification by hydrophilic probes [89,139,140].
In several cases, analysis of our models suggests
some alternative interpretations of previously pub-
lished experimental data. For example, in theβ2-
adrenergic receptor model themeta-hydroxy group
of the ligand’s catechol ring forms an H-bond with
Ser204(V:7), as has previously been suggested from
decreased binding of isopreterenol analogs to the
S204A (V:7) mutant of theβ2-adrenergic receptor
[102,125]. However, thepara-hydroxy group of the
catechol ring forms an H-bond with Asn293(VI:23),
instead of with Ser207(V:10), as has been proposed
based upon mutagenesis data [102]. The uncertain role
of serine residues of helix V in H-bonding with adren-
ergic ligands has recently been debated in the litera-
ture [71,141,142]. In our adrenergic receptor models,
Ser207(V:10), which is conserved in the amine recep-
tor subfamily, does not interact directly with ligands
but rather participates in an H-bond network between
helices III, IV, and V, formed by the side-chains of
Glu122(III:16), Ser161(IV:14), and Ser207(V:10), all of
which are conserved inβ-receptors. Thus, replace-
ments of Ser207(V:10) would be expected to primarily
affect activation of the receptor. In fact, this is consis-
tent with the data of Strader et al. [102], which show
that the binding of an isoproterenol analog with only
a para-hydroxy substituent to the S207A mutant was
virtually unaffected but that activation of the mutant
receptor was profoundly diminished. Similar results
indicating an important role of Ser(V:10) in receptor
activation have been obtained more recently for sev-
eral other cationic amine receptors [104,105,135,136].
Conclusions
We have described, above, some of the general fea-
tures of the 7-α-helical domains of 26 different GPCRs
and two related proteins, retinochrome and the Duffy
erythrocyte antigen, calculated using a distance geom-
etry approach. The computational procedure repre-
sents a ‘large-scale’ refinement of an approximate
model of the transmembrane 7-α-bundle constructed
from electron microscopy and other experimental data.
This refinement of theα-bundle was not based on
energy minimization, since the existing theoretical ap-
proaches do not allow calculation of the appropriate
energy. Instead, structural constraints encoded in the
multiple sequence alignments of GPCRs, i.e. the ex-
perimental data provided by natural mutagenesis and
natural selection during many millions of years of
evolution, were used.
The rhodopsin-like GPCR family includes hun-
dreds of proteins with amino acid sequence identities
in the range of 20–99%. Comparisons of GPCRs with
low sequence identity are especially informative, since
such receptors feature alternative versions of side-
chain packing which must be accommodated within
the same, common 3D structure. Site-directed muta-
genesis studies of many proteins indicate that replace-
ments of inner, tightly packed residues are usually
destructive, and that the design of stable and func-
tional mutants with an alternatively repacked ‘core’
is a challenging problem, since this requires corre-
lated, compensatory replacements of several interact-
ing residues. The GPCR family, however, provides a
multitude of such correlated replacements in the core
created by natural selection, which can be transformed
into structural constraints.
The correlated replacement of core residues dur-
ing protein evolution is accomplished such that the
interacting side-chains of the transmembrane helices
maintain matching polarities, provide geometrically
close packing, and, if polar, form interhelical H-bonds.
Only these H-bonds, collected from many different
GPCRs, were used for calculations of theα-bundle,
since they give the most unequivocal and restrictive
distance constraints. Nevertheless, the analysis of the
28 calculated structures reveals not only ‘saturation
of H-bond potential’ for buried polar side-chains, but
also close packing of nonpolar side-chains, the forma-
tion of extensive aromatic and sulfur–aromatic clusters
(aromatic residues usually separate polar and aliphatic
regions, creating polarity gradients), an anisotropic
distribution of lipid-facing side-chains whose polari-
ties match the nonpolar tails and polar head groups of
the lipids, the formation of a regulatory Na+-binding
site, and the existence, in many GPCRs, of interhelical
disulfide bonds. The models are further character-
ized by a single, common ligand-binding region that,
for 17 GPCRs examined, is complementary in shape
and polarity to the corresponding native and synthetic
ligands. Moreover, the models of bovine rhodopsin,
opioid, and cationic amine receptors are consistent
with a vast sample of published experimental data.
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